These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
611 related articles for article (PubMed ID: 22343920)
61. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102 [TBL] [Abstract][Full Text] [Related]
62. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740 [TBL] [Abstract][Full Text] [Related]
64. Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies. Ivanova M; Shivarov V; Pavlov I; Lilakos K; Naumova E Mol Diagn Ther; 2016 Feb; 20(1):27-32. PubMed ID: 26476543 [TBL] [Abstract][Full Text] [Related]
65. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts. Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018 [TBL] [Abstract][Full Text] [Related]
67. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome. Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121 [TBL] [Abstract][Full Text] [Related]
68. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598 [TBL] [Abstract][Full Text] [Related]
69. The Genetics of Myelodysplastic Syndromes: Clinical Relevance. Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317 [TBL] [Abstract][Full Text] [Related]
70. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Patnaik MM; Padron E; LaBorde RR; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Al-kali A; Pardanani A; Ali NA; Komrokji RS; Tefferi A Leukemia; 2013 Jul; 27(7):1504-10. PubMed ID: 23531518 [TBL] [Abstract][Full Text] [Related]
71. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes. Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529 [TBL] [Abstract][Full Text] [Related]
72. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Yang L; Wei X; Gong Y Cancer Med; 2024 Jan; 13(1):e6871. PubMed ID: 38146893 [TBL] [Abstract][Full Text] [Related]
73. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985 [TBL] [Abstract][Full Text] [Related]
74. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview. Jhanwar SC Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150 [TBL] [Abstract][Full Text] [Related]
75. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Patnaik MM; Lasho TL; Hodnefield JM; Knudson RA; Ketterling RP; Garcia-Manero G; Steensma DP; Pardanani A; Hanson CA; Tefferi A Blood; 2012 Jan; 119(2):569-72. PubMed ID: 22096241 [TBL] [Abstract][Full Text] [Related]
76. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Damm F; Thol F; Kosmider O; Kade S; Löffeld P; Dreyfus F; Stamatoullas-Bastard A; Tanguy-Schmidt A; Beyne-Rauzy O; de Botton S; Guerci-Bresler A; Göhring G; Schlegelberger B; Ganser A; Bernard OA; Fontenay M; Heuser M Leukemia; 2012 May; 26(5):1137-40. PubMed ID: 22064355 [No Abstract] [Full Text] [Related]
77. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center]. Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186 [No Abstract] [Full Text] [Related]